Altercating Leishmaniasis: Cultivating Improved Vaccines

Neha Dhingra¹, Sandeep Satapathy²,*

¹Department of Zoology, University of Delhi, Delhi, India
²Department of Biological Sciences, Indian Institute of Science Education and Research, Bhopal, India
*Corresponding Author: sandeeps@iiserb.ac.in

Copyright © 2014 Horizon Research Publishing All rights reserved.

Abstract The exponentially rising cases of Leishmaniasis over the past decades, has attracted scientists and clinicians to mitigate the contagious infection by modern treatments and new generation vaccinations. *Leishmania*, the causative pathogen of this infection predominantly expresses its diseased condition in form of cutaneous leishmaniasis. Although systemic leishmaniasis, is a more deadly form, but cases of its manifestation are limited; thereby staging the focus onto more intricate study of cutaneous leishmaniasis. Designing a vaccine against Leishmania has witnessed more than two generations of vaccine, but each attempt has failed more than it’s cases of success. The proposed drawbacks root to the difficulty in ensuring an efficient transition of research from simple laboratory experiments carried out *in-vitro/in-vivo* in small animals to that of the humans. There have been extensive case studies of this disease and thus every immunological aspect has been our focus. This paper is an attempt to decipher the ideas and methodologies adopted till date and further target the genetic spans and molecular moieties, for crafting an alternative vaccine based on efforts to mock the pathogenic pathways.

Keywords Cutaneous, Proteomics, Recombinant DNA, Macrophage, Life Cycle, Live-attenuated Vaccines

1. Introduction

Leishmaniasis caused by the genus *Leishmania*, has been classified as one of the most neglected diseases [5]. For many years, the public health influence of leishmaniasis has been underestimated [6]. The expansion of leishmaniasis and the sharp rise in occurrence is related to environmental changes and migration of non-immune people to endemic areas [6]. *Leishmania* parasites are responsible for a family of diseases, collectively known as leishmaniasis, with discrete clinical features ranging from cutaneous lesions to fatal systemic diseases [6, 5]. There are several diverse forms of leishmaniasis in individuals (fig.1). Some people have a silent infection of leishmania, without any signs or symptoms of the infection.

Figure 1. Forms of Leishmaniasis: Ranging from acute to chronic disease manifestation.

The visceral form, also known as black sickness or kala-azar is an Indian name, meaning "black fever" (darkening of the skin) in Asia, is characterized by prolonged fever, splenomegaly, hepatomegaly, substantial weight loss, progressive anemia, pancytopenia, and hypergammaglobulinemia and is complicated by serious infections [3]. After recovery, some patients also develop post-kala-azar dermal leishmaniasis [PKDL], which requires prolonged and expensive treatment. Natural transmission of leishmania is carried out by a certain species of sand fly of the genus *Lutzomyia* [15].

An increasing resistance to the currently used drugs, their side effects and more importantly, the lack of efficient vaccines has been the major boost for growing research in this field. [19]. Precisely, intensive study of the parasite has also demanded a thorough analysis of the host-pathogen interactions for designing the ultimate HERO ANTI-LEISHMANIA vaccine. Although, studies of several model organisms especially mice, heralded the scope of solid protection that can be reached upon by immunization with defined subunit vaccines [either protein or DNA] or heat-killed parasites, but, to date the test results of such vaccines have seen unsatisfactory fates. [10].

1.1. Leishmanial Stages

*Leishmania* spp., known to be a digenetic parasites, involves two hosts, a vertebrate- is the amastigote (the intracellular form in the vertebrate host) and an invertebrate- the promastigote (the extracellular form in the sand-fly)[5].
Amastigotes can be isolated from the blood of an infected host when the female sand fly bites, and in the sand fly gut they are designated as promastigotes during the time of their residence. In the gut they multiply by binary fission; followed by anterior movement into the proboscis, and are introduced into the vertebrate host upon the bite of sand fly to its host. The injected promastigotes inside the host are phagocytized while feeding and develop into intracellular amastigotes [14, 5].

Amastigotes are set up in cells of the reticulo-endothelial system of vertebrate hosts [skin, bone marrow, liver, spleen, and lymph nodes]. In large mononuclear cells, instances of their presence in the bloodstream have been confirmed [4,29,32].

After initial ingestion of blood meal from the host, promastigotes development in the sand fly takes 8-20 days, and followed by multiplication in the midgut-hindgut, they move forward to the pharynx where they produce a partial or complete blockage of the sucking apparatus. When such a sand fly tries to feed it, an upward movement of bolus of metacyclic promastigotes occurs which is then inserted into the bite wound [10,21,26].

1.2. Alternative Pathogenicity of Parasites

L. major lacks the gene for the potential target enzymes, and in such a case pathogenicity is rendered by the presence of Serine protease inhibitors [ISPs]. The ISPs have inhibitory effects against vertebrate macrophage serine proteases, such as neutrophil elastases [39]. Case of ISPs interfering in trypsin-like action of sand fly midguts has been reported [25]. Moreover, a few parasites of Leishmania family also have mechanisms that intensify their resistance to proteolytic attack without inhibiting the overall proteolytic activity in the midgut [28].

The results of Secundino et al [47] focused on L. major surface PPG (proteophosphoglycan) as the likely key molecule conferring resistance of fully developed procyclic promastigotes to the activity of digestive enzymes; showing that a parasite line lacking surface PGs is more susceptible to killing than the wild type when exposed to blood-fed midgut lysates [12]. However, addition of purified PPG is known to classically reverse this effect [22]. Further the sand fly midgut proteolytic enzymes are negative effectors on the Leishmania growth in the vector and therefore, can be categorized as attractive targets for vector-based transmission blocking strategy [32].

1.3. Proteins and Peptides Involved

Innate immune response- Defensins, cationic antibacterial peptides have been defined in the fat body and the midgut. [70] Transcripts coding for numerous other putative components of the innate immune response have been discovered in the sand fly midgut, such as pattern recognition proteins, a glycine-rich protein and serpins. Antioxidant enzyme’s homologues, which can regulate midgut epithelial immunity and dictate the fate of bacterial and parasitic infections in mosquitoes, have also been found [21, 23,24,43,46,47]. Recently it has been established that in L. longipalpis, depletion of Caspar (a putative negative regulator of immune deficiency signaling pathway) by RNAi prior to blood feeding, results in significant reduction of populations of both L. mexicana and L. infantum. The major vivid inference is that, the growth and spread of leishmaniasis is crosschecked by several levels of systemic immune response[35, 42, 47].
1.4. Alteration of Macrophage Signaling Molecules by Leishmania

Two major strategies adopted by Leishmania to alter the macrophage signaling pathway are: inhibition of proteins that play a positive role in immune cell activation and activation of molecules known to play key roles in the negative regulation of immune cell signaling and function (Fig.2) [14].

Critical Survival Strategies developed by parasite to ensure smooth residence inside the macrophages are:

- The parasite is able to induce the chemokine expression and production by host immune cells [36]. It has been shown that the infection of mice with L. major upregulated the gene expression of several chemokines [RANTES/CCL5, MIP-1α/CCL3, IP-10/CXCL10, and MCP-1/CCL2] in cells collected from the footpad and their draining lymph nodes [16].

- L. major infection results in higher levels of several chemokines [RANTES, MIP-1α, MIP-1β/CCL4, IP-10, MCP-1, and MIP-2/CXCL1] in cells characterised by their fast recruitment at the site of infection [61]. To add importance to this finding it has been shown that in general a large population of chemokines are monocytchemoattractants recruiting macrophages to infected tissues and immobilizing the parasite [26].

- Protein kinase C [PKC] signaling acts as a key regulator of macrophage functioning; e.g. cytokines such as IFN-γ and TNF-α, both crucial in driving several functions including NO production and oxidative burst [8, 10]. Promastigote LPG has been identified as an antagonist of PKC [11] which is manifested by the competitive binding of LPG to the regulatory domain of PKC which contains the Diacylglycerol (DAG), Ca^{2+}, and phospholipid binding sites. [29].

- Leishmania encounters macrophages which are capable of producing deadly free radicals such as NO and reactive oxygen intermediates (ROIs) [35]. To escape this, the parasite has the ability to block the JAK/STAT signaling pathway in response to IFN-γ stimulation, suppressing the induction of NO [41]. However, cases have been reported where Leishmania affects Jak2 phosphorylation by rapidly activating host SHP-1 leading to the subsequent inhibition of IFN-γ-induced Jak2 phosphorylation [30]. It has been observed that IFN-γ unresponsiveness to stimulation can be due to the inhibition of the IFN-γ receptor [IFN-γR] complex formation [33, 27, 21].

- As a key by-passing policy Leishmania parasite develop tactics to deactivate several MAPK members post parasite intrusion into macrophages or by activating stimuli that follow infection [24]. For instance, the phagocytosis of L. donovani promastigotes by naive macrophages does not lead to the activation of any of the three MAPKs [Erk1/2, JNK, p38].

- In respect to p38, stimulation with a CD40 antibody (mimicking the macrophages-T cell interaction) has been effective in generating nonresponsiveness to MAPK, even when macrophages are infected with L. major; [31]. Leishmanicidal functions get impaired in context of p38 inactivation with suppression iNOS2 expression and NO production [31].

- In order to inhibit gene expression of proinflammatory cytokines and microbicidal molecules, Leishmania develop several strategies to interfere with transcription factors that bind to the promoters of these genes [31, 32].

1.5. Modulation of Toll-Like Receptor Signaling by Leishmania

TLR family members are classical mediators of both innate and adaptive immune response through their potential ability of recognition of pathogen-associated molecular patterns [PAMPs] [17].

- GPI-anchored proteins, are a group of parasite-derived molecules involved in TLR binding and activation. TLR signalling in primary exposure induces tolerance to secondary TLR stimulation [19]. This was later known to be mediated by the ability of GPI-mucin to induce the expression and activation of the serine/threonine phosphatase PP2A that acts on cellular IRAK-1, MAPKs, and IκB causing their inhibition and leading to tolerance [11]. The induction of PP2A was shown to require p38 and NF-κB, the very same molecules PP2A is induced to inhibit, therefore giving rise to an auto regulatory loop [10].

- LPG of Leishmania is another GPI-anchored protein detected by TLRs. It has been shown that LPG of L. major directly binds to TLR2 of Macrophages and NK cells [11, 12] and that LPG of L. donovani is also detected by TLR2 of activated Macrophages [13].

Also the non-GPI-related ligands are sensed by the TLRs. DNA of T. cruzi, T. brucei and Babesia bovis, are able to activate macrophages and Dendritic cells [18, 19] in lieu of their unmethylated CpG motifs [20] which can be detected by TLR9 [21, 22].

TLRs as potent parasitic PAMPs detector along with multi-faceted responsiveness in cases of successful infections raise questions associated with silent entry to target cells, suggesting parasitic techniques evading of host TLR signaling pathways.

It is clear that TLRs play a crucial role in mounting innate and adaptive immunity against invading pathogens [1, 13]. Nevertheless, the effects of blocking TLR-TLR-ligand interactions on the ability of the immune system to fight off
other pathogens that can be/become present and thereby needs to be taken into serious consideration.

2. Implications of Leishmanial-diagnosis

2.1. Antigen Detection

De Colmenares et al. [20] from Spain have reported two polypeptide fractions of 72-75 kDa and 123 kDa in the urine of kala-azar patients. The sensitivities of the 72-75-kDa fractions were 96%, and the specificities were 100%.

A new latex agglutination test [KATEX] for detecting leishmanial antigen in urine of patients with VL has showed sensitivities between 68 and 100% and a specificity of 100% in preliminary trials. The antigen is detected quite early during the infection and the results of animal experiments suggest that the amount of detectable antigen tends to decline rapidly following chemotherapy [17,24].

2.2. Antibody Detection

Conventional methods for antibody detection include gel diffusion, complement fixation test, indirect hemagglutination test, IFA test, and counter current immunoelectrophoresis [2, 13]. However, aside from practical difficulties at peripheral laboratories, the sensitivities and specificities of most of the above tests have been the limiting factors [36]. In 1988, a modified DAT was reported to be useful in kala-azar and is being used in several countries of endemicity [27].

2.3. Western Blot

Specific antibodies can also be detected by Western blotting [38]. In this diagnostic method, promastigotes of L. donovani are grown to log phase and lysed and the soluble protein is used as sample [18]. With Western blotting, one can find even minor antigenic differences among various organisms and thus detect cross-reactive antigens [28]. Though, the process is time consuming, technically cumbersome, and expensive [8].

The diagnostic principles remain essentially the same as those for non-HIV-infected patients [8]. For HIV patients, the sensitivity of antibody-based immunologic tests like the IFA test and ELISA is low [3,4]. Since the parasite load is quite heavy in these patients, the presence of leishmania amastigotes in the bone marrow can be verified.

3. Overview of Vaccine Development

The comparatively straightforward leishmanial life cycle and the point that recovery from a primary infection provides the host resistance to subsequent infections, indicate the feasibility of vaccination [10].

- First generation vaccines; represented by whole killed parasites, have been proposed as both prophylactic and therapeutic vaccines [32]. These whole-cell killed vaccines with undefined and variable in potency, have been fated with limited success rates [11].
- Second generation vaccines consist of recombinant proteins, poly-proteins, DNA vaccines or dendritic cells loaded with peptides derived from leishmanial antigens [33]. A GPI-anchored membrane protein gp46 or Parasite Surface Antigen 2 (present in most Leishmania species) has also been identified as a suitable vaccine candidate [34]. PSA-2 results in macrophage invasion through the interaction of its leucine rich repeats with complement receptor [35]. Immunization with the native polypeptides derived from promastigotes protected mice against infection, in contrast to vaccination with a recombinant protein derived from either promastigotes or amastigotes protein showed lack of protective efficacy[37]. DNA vaccination conferred protection in mice when used as either prophylactic[38] or therapeutic vaccines[39]. For instance, one more extensively tested antigen is the Leishmania homologue for receptors of activated C kinase [LACK] that is expressed throughout leishmanial life cycle[40]. Immunization with LACK appears to promote the expansion of IL-4 secreting T cells twisting the response towards detrimental Th2 responses[41].
- Statistically, only one second generation vaccine, Leish-111f (a single polypeptide composed of three molecules fused; the L. major homologue of eukaryotic thiol-specific antioxidant [TSA], the L. major stress-inducible protein-1 [LmST11] and the L. braziliensis elongation and initiation factor [LeIF][25]), has been assessed in clinical trials[15,45]. Initial immunisation trials in mice confirmed that Leish-111f was able to protect mice against L. major and L. amazonensis infection[36, 46].

Sand fly saliva contains an array of molecules able to interfere with the host immune responses, therefore; immunity against saliva components may indirectly enhance anti-leishmanial immunity [36]. Immunization with molecules present in saliva, such as maxadilan [22] or a 15-kDa protein, SP15 [36] also induced protection against cutaneous leishmaniasis [22]. Recently, it has been shown that vector salivary proteins, in particular LJM19, protect hamster from VL, [44] and immunization of dogs with salivary antigens led to the development of high IgG2 antibody levels and significant IFN-γ production [35].

3.1. Live-attenuated Leishmania—An Alternative Vaccine Approach

The live-attenuated vaccine exhibits a complete spectrum of antigens to the antigen presenting cells, ultimately leading...
to a better immune response in comparison to that of a subunit vaccine.

Avirulent microorganisms crafted by a defined genetic manipulation, restricting the reversion of pathogenicity. Only a minority of attenuated strains has been tested so far with many outcomes, and the live attenuated, antileishmanial vaccine is still at its initial stages of expansion. Recently, *L. donovani* centrin (a calcium-binding cytoskeletal protein involved in the duplication of centrosomes in higher eukaryotes) null mutants (LdCEN−/−) have been reported to have selective growth arrest in the amastigote stage of development, but were viable in culture as promastigotes [22]. These mutants were unable to survive in vitro in human macrophages and animals vaccinated with LdCEN−/− mutants were protected against homologous as well as heterologous challenge [23]. It has lately been confirmed that *L. major* phosphomannomutase [PMM] deficient mutants were able to defend susceptible mice beside infection via an increased magnitude of T cell responses and suppression of IL-10 and IL-13 production early during infection [44].

Another example of an attenuated vaccine that displayed protective efficacy is *L. infantum SIR2* single knockout strain, [77] however; the integral problem of this strain is the existence of the second SIR2 allele making reversion to virulence a possible occurrence.

### 3.2. Impediments for Vaccine Designing

Vaccination is the best answer to question pertaining to infectious diseases. Leishmaniasis should be manageable by immunization, seems irrefutable in context of the existing experimental evidences. Therefore, understanding the shortcomings of the marketed vaccines is crucial to future stages of anti-leishmanial vaccine designing.

Insights into antileishmanial immunity explain the catastrophic existence of the first generation vaccines. Peters *et al* demonstrated that sand fly transmission of parasites abo disrupts vaccine-induced protective immunity [32]. Mice vaccinated with killed parasites, were stubborn to a needle challenge, and were then prone to the sand fly inoculum inferring that the responses in vaccinated mice required for defense were either not generated or not preserved. On the other hand, mice that had cured the primary lesion were protected against sand fly challenge, and the swiftness of the response proposes that the protective response was not resultant from the central memory, rather from an effector pool of T cells that could have been preserved by the persistent parasites. This data provides a foundation for the inclusion of sand fly saliva components, which are specific to natural infection. It has been established that inoculation of killed parasites into immune mice leads to a loss of infection induced immunity [38].

Selection of vaccine candidates has continued to be a really difficult problem. An excess of antigens have been calculated with mixed success dependent on the formulation and the animal model used for testing it. However, complete protection has not been reached so far and immunization has generally led only to partial protection. In addition, the opinions on the nature of the vaccine have been at odds. Some claim that a vaccine against leishmaniasis should be molecularly defined, while others say for a live attenuated vaccine.

One of the major problems a vaccine faces against leishmaniasis, are alterations in virulence factors among the species as well as in the immune responses that they induce. For example, LPG is a virulence factor for *L. major*, [45] but not for *L. mexicana* [46] During the *L. major* infection the defensive role of Th1 responses has been established, but *L. amazonensis* is able to survive in the presence of Th1 responses, and causes minimal disease in the complete absence of T cells [47]. Studies explaining parasite-vector interactions have become the basis for novel approaches to reduce transmission of numerous insect-borne ailments.

### 4. Conclusion

The main concern over the issue of development of vaccines for leishmaniasis is no different from other diseases that are encountered. They target the specificity, the class or type of response made, and the promotion of long-term immunological memory of the disease. This review gives an insight into the developing world of vaccinations where first line of vaccination and subsequently the second line of vaccination could not bring us the possible results as desired. This review focuses on advances in anti-leishmania vaccine development over the current years and examines current problems that are hampering vaccine development and implementation in leishmaniasis.

### REFERENCES

[1] M. Olivier, D. J. Gregory, and G. Forget, “Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view,” Clinical Microbiology Reviews, vol. 18, no. 2, pp. 293–305, 2005.

[2] M. E. Reyland, “Protein kinase C isoforms: multi-functional regulators of cell life and death,” Frontiers in Bioscience, vol. 14, pp. 2386–2399, 2009.

[3] S. Ghosh, S. Bhattacharyya, S. Das et al., “Generation of ceramide in murine macrophages infected with Leishmania donovani alters macrophage signaling events and aids intracellular parasitic survival,” Molecular and Cellular Biochemistry, vol. 223, no. 1-2, pp. 47–60, 2001.

[4] J. S. Rawlings, K. M. Rosler, and D. A. Harrison, “The JAK/STAT signaling pathway,” Journal of Cell Science, vol. 117, no. 8, pp. 1281–1283, 2004.

[5] I. Woldman, L. Varinou, K. Ramsauer, B. Rapp, and T. Decker, “The stat1 binding motif of the interferon-γ receptor is sufficient to mediate stat1 activation and its repression by SOCS3,” The Journal of Biological Chemistry, vol. 276, no. 49, pp. 45722–45728, 2001.
promastigotes evade the activation of mitogen-activated protein kinases p38, c-Jun N-terminal kinase, and extracellular signal-regulated kinase-1/2 during infection of naive macrophages,” European Journal of Immunology, vol. 30, no. 8, pp. 2235–2244, 2000.

9. G. Forget, D. J. Gregory, L. A. Whitcombe, and M. Olivier, “Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production,” Infection and Immunity, vol. 74, no. 11, pp. 6272–6279, 2006.

10. S. Ghosh, S. Bhattacharyya, M. Sirkar et al., “Leishmania donovani suppresses activated protein 1 and NF-κB activation in host macrophages via ceramide generation: involvement of extracellular signal-regulated kinase,” Infection and Immunity, vol. 70, no. 12, pp. 6828–6838, 2002.

11. P. Cameron, A. McGachy, M. Anderson et al., “Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cysteine proteases and the NF-κB signaling pathway,” The Journal of Immunology, vol. 173, no. 5, pp. 3297–3304, 2004.

12. A. Awasthi, R. Mathur, A. Khan et al., “CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response,” Journal of Experimental Medicine, vol. 197, no. 8, pp. 1037–1043, 2003.

13. M. Junghae and J. G. Raynes, “Activation of p38 mitogen-activated protein kinase attenuates Leishmania donovani infection in macrophages,” Infection and Immunity, vol. 70, no. 9, pp. 5026–5035, 2002.

14. L. Guizani-Tabbane, K. Ben-Aissa, M. Belghith, A. Sassi, and K. Delli, “Leishmania major amastigotes induce p50/c-Rel NF-κB transcription factor in human macrophages: involvement in cytokine synthesis,” Infection and Immunity, vol. 72, no. 5, pp. 2582–2589, 2004.

15. D. J. Gregory, M. Godbout, I. Contreras, G. Forget, and M. Olivier, “A novel form of NF-κB is induced by Leishmania infection: involvement in macrophage gene expression,” European Journal of Immunology, vol. 38, no. 4, pp. 1071–1081, 2008.

16. G. Forget, D. J. Gregory, and M. Olivier, “Proteasome-mediated degradation of STAT1α following infection of macrophages with Leishmania donovani,” The Journal of Biological Chemistry, vol. 280, no. 34, pp. 30542–30549, 2005.

17. J. V. Ravetch and L. L. Lanier, “Immune inhibitory receptors,” Science, vol. 290, no. 5489, pp. 84–89, 2000.

18. I. Contreras, M. A. Gómez, O. Nguyen, M. T. Shio, R. W. McMaster, and M. Olivier, “Leishmania-induced inactivation of the macrophage transcription Factor AP-1 is Mediated by the Parasite Metalloprotease GP63,” PLoS Pathogens, vol. 6, no. 10, Article ID e1001148, 2010.

19. M. Larsen, M. L. Tremblay, and K. M. Yamada, “Phosphatases in cell-matrix adhesion and migration,” Nature Reviews Molecular Cell Biology, vol. 4, no. 9, pp. 700–711, 2003.

20. L. I. Pao, K. Badour, K. A. Siminovich, and B. G. Neel, “Nonreceptor protein-tyrosine phosphatases in immune cell signaling,” Annual Review of Immunology, vol. 25, pp. 473–523, 2007.

21. M. Elchebly, A. Cheng, and M. L. Tremblay, “Modulation of insulin signaling by protein tyrosine phosphatases,” Journal of Molecular Medicine, vol. 78, no. 9, pp. 473–482, 2000.

22. M. P. Myers, J. N. Andersen, A. Cheng et al., “TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B,” The Journal of Biological Chemistry, vol. 276, no. 51, pp. 47771–47774, 2001.

23. M. A. Gomez, I. Contreras, M. Hallé, M. L. Tremblay, R. W. McMaster, and M. Olivier, “Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases,” Science Signaling, vol. 2, no. 90, article ra58, 2009.

24. P. D. Simoncic, A. Lee-Loy, D. L. Barber, M. L. Tremblay, and C. J. McGlade, “The T cell protein tyrosine phosphatase is a negative regulator of Janus family kinases 1 and 3,” Current Biology, vol. 12, no. 6, pp. 446–453, 2002.

25. J. Ten Hoeve, M. D. J. Ibara-Sanchez, Y. Fu et al., “Identification of a nuclear Stat1 protein tyrosine phosphatase,” Molecular and Cellular Biology, vol. 22, no. 16, pp. 5662–5668, 2002.

26. M. Hallé, M. A. Gomez, M. Stuible et al., “The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38mitogen-activated protein kinase inactivation,” The Journal of Biological Chemistry, vol. 284, no. 11, pp. 6893–6908, 2009.

27. D. Nandan, T. Yi, M. Lopez, C. Lai, and N. E. Reiner, “Leishmania EF-1α activates the Src homology 2 domain containing tyrosine phosphatase SHP-1 leading to macrophage deactivation,” The Journal of Biological Chemistry, vol. 277, no. 51, pp. 50190–50197, 2002.

28. S. Antoniazzi, H. P. Price, K. Kropf et al., “Chemokine gene expression in Toll-like receptor-competent and -deficient mice infected with Leishmania major,” Infection and Immunity, vol. 72, no. 9, pp. 5168–5174, 2004.

29. G. Forget, C. Matte, K. A. Siminovich, S. Rivest, P. Pouliot, and M. Olivier, “Regulation of the Leishmania-induced innate inflammatory response by the protein tyrosine phosphatase SHP-1,” European Journal of Immunology, vol. 35, no. 6, pp. 1906–1917, 2005.

30. M. J. Teixeira, C. R. Teixeira, B. B. Andrade, M. Barral-Netto, and A. Barral, “Chemokines in host-parasite interactions in leishmaniassias,” Trends in Parasitology, vol. 22, no. 1, pp. 32–40, 2006.

31. D. Rousseau, S. Demartino, F. Anjuère et al., “Sustained parasite burden in the spleen of Leishmania infantum-infected BALB/c mice is accompanied by expression of MCP-1 transcripts and lack of protection
against challenge,” European Cytokine Network, vol. 12, no. 2, pp. 340–347, 2001.

[32] P. Das, A. Lahiri, A. Lahiri, and D. Chakravortty, “Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator,” PLoS Pathogens, vol. 6, no. 6, Article ID e1000899, 2010.

[33] J. Osorio y Forteà, E. de La Llave, B. Regnault et al., “Transcriptional signatures of BALB/c mouse macrophages housing multiplying Leishmania amazonensis amastigotes,” BMC Genomics, vol. 10, article 119, 2009.

[34] R. Lodge, T. O. Diallo, and A. Descoteaux, “Leishmania donovani lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane,” Cellular Microbiology, vol. 8, no. 12, pp. 1922–1931, 2006.

[35] R. Lodge and A. Descoteaux, “Phagocytosis of Leishmania donovani amastigotes is Rac1 dependent and occurs in the absence of NADPH oxidase activation,” European Journal of Immunology, vol. 36, no. 10, pp. 2735–2744, 2006.

[36] A. Fontayne, P. M. C. Dang, M. A. Gougerot-Pocidalo, and J. El Benna, “Phosphorylation of p47phox sites by PKC α, βII, δ, and ζ: effect on binding to p22phox and on NADPH oxidase activation,” Biochemistry, vol. 41, no. 24, pp. 7743–7750, 2002.

[37] R. M. Mukbel, C. Patten, K. Gibson, M. Ghosh, C. Petersen, and D. E. Jones, “Macrophage killing of Leishmania amazonensis amastigotes requires both nitric oxide and superoxide,” American Journal of Tropical Medicine and Hygiene, vol. 76, no. 4, pp. 669–675, 2007.

[38] M. Del Vecchio, E. Bajetta, S. Canova et al., “Interleukin-12: biological properties and clinical application,” Clinical Cancer Research, vol. 13, no. 16, pp. 4677–4685, 2007.

[39] I. Abu-Dayyeh, M. T. Shio, S. Sato, S. Akira, B. Cousineau, and M. Olivier, “Leishmania-induced IRAK-1 inactivation is mediated by SHP-1 interacting with an evolutionarily conserved KTIM motif,” PLoS Neglected Tropical Diseases, vol. 2, no. 12, article e305, 2008.

[40] M. C. De Almeida, S. A. Cardoso, and M. Barral-Netto, “Leishmania (Leishmania) chagasi infection alters the expression of cell adhesion and costimulatory molecules on human monocyte and macrophage,” International Journal for Parasitology, vol. 33, no. 2, pp. 153–162, 2003.

[41] C. Ropert and R. T. Gazzinelli, “Regulatory role of toll-like receptor 2 during infection with Trypanosoma cruzi,” Journal of Endotoxin Research, vol. 10, no. 6, pp. 425–430, 2004.

[42] A.-C. Oliveira, J. R. Peixoto, L. B. De Arrada et al., “Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycosylphosphatidylcholipids and higher resistance to infection with T. cruzi,” The Journal of Immunology, vol. 173, no. 9, pp. 5688–5696, 2004.

[43] C. Ropert, M. Clozel, A. C. L. Chaves, and R. T. Gazzinelli, “Inhibition of a p38/stress-activated protein kinase-2-dependent phosphatase restores function of IL-1 receptor-associated kinase-1 and reverses Toll-like receptor 2- and 4-dependent tolerance of macrophages,” The Journal of Immunology, vol. 171, no. 3, pp. 1456–1465, 2003.

[44] M. J. de Veer, J. M. Curtis, T. M. Baldwin et al., “MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling,” European Journal of Immunology, vol. 33, no. 10, pp. 2822–2831, 2003.

[45] I. Becker, N. Salaiza, M. Aguirre et al., “Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2,” Molecular and Biochemical Parasitology, vol. 130, no. 2, pp. 65–74, 2003.

[46] J. F. Flandin, F. Chano, and A. Descoteaux, “RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-γ primed macrophages,” European Journal of Immunology, vol. 36, no. 2, pp. 411–420, 2006.

[47] F. Debierre-Grockiego, M. A. Campos, N. Azzouz et al., “Activation of TLR2 and TLR4 by glycosylphosphatidylinositolcs derived from Toxoplasma gondii,” The Journal of Immunology, vol. 179, no. 2, pp. 1129–1137, 2007.